Nelson L Michael
Michael, Nelson L.
Michael, Nelson
VIAF ID: 39551076 (Personal)
Permalink: http://viaf.org/viaf/39551076
Preferred Forms
-
200 _ |
‡a
Michael
‡b
Nelson L.
-
100 1 0
‡a
Michael, Nelson
-
100 1 _
‡a
Michael, Nelson L.
-
100 1 _ ‡a Michael, Nelson L.
-
100 1 _
‡a
Michael, Nelson L.
-
100 0 _
‡a
Nelson L Michael
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| HIV protocols |
|
| Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study |
|
| Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual |
|
| Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance. |
|
| Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations |
|
| Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees |
|
| Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials |
|
| Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification |
|
| Medical encounter characteristics of HIV seroconverters in the US Army and Air Force, 2000–2004. |
|
| Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling |
|
| Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans |
|
| Molecular epidemiology of early and acute HIV type 1 infections in the United States Navy and Marine Corps, 2005-2010. |
|
| Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial |
|
| Natural killer cell-mediated innate sieve effect on HIV-1: the impact of KIR/HLA polymorphism on HIV-1 subtype-specific acquisition in east Africa |
|
| Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones. |
|
| Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes |
|
| Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound |
|
| Next-generation sequencing of HIV-1 single genome amplicons |
|
| The Number and Complexity of Pure and Recombinant HIV-1 Strains Observed within Incident Infections during the HIV and Malaria Cohort Study Conducted in Kericho, Kenya, from 2003 to 2006 |
|
| Oral Preexposure Prophylaxis for HIV — Another Arrow in the Quiver? |
|
| PCR amplification, cloning, and construction of HIV-1 infectious molecular clones from virtually full-length HIV-1 genomes. |
|
| Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge |
|
| Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. |
|
| Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection |
|
| Phambili: moving forward without the blindfold |
|
| Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate |
|
| Pilot studies for development of an HIV subtype panel for surveillance of global diversity |
|
| Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial |
|
| Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines |
|
| Population-based Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis prevalence using discarded, deidentified urine specimens previously collected for drug testing |
|
| Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor |
|
| Pre-deployment Alcohol Misuse Among Shipboard Active-Duty U.S. Military Personnel |
|
| Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals |
|
| Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers |
|
| Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning of the National Antiretroviral Therapy Program |
|
| Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16-STING-Type I IFN Pathway and AIM2 Sensor. |
|
| Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences |
|
| Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort. |
|
| Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand |
|
| Prospects for a Zika Virus Vaccine |
|
| The protective effect of circumcision on HIV incidence in rural low-risk men circumcised predominantly by traditional circumcisers in Kenya: two-year follow-up of the Kericho HIV Cohort Study |
|
| Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys |
|
| Q&A with Nelson Michael. Interview by Andreas von Bubnoff |
|
| Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting |
|
| Quantitative analyses reveal distinct sensitivities of the capture of HIV-1 primary viruses and pseudoviruses to broadly neutralizing antibodies |
|
| Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial |
|
| Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection |
|
| Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys |
|
| Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection |
|
| Rare serotype adenoviral vectors for HIV vaccine development |
|
| RecDraw: a software package for the representation of HIV-1 recombinant structures. |
|
| Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination |
|
| Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity |
|
| Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials |
|
| Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya |
|
| Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda |
|
| Review of the U.S. military's human immunodeficiency virus program: a legacy of progress and a future of promise |
|
| Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. |
|
| Risk factors for HIV-1 infection in a longitudinal, prospective cohort of adults from the Mbeya Region, Tanzania |
|
| The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization |
|
| Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene |
|
| Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial |
|
| Safety and Immunogenicity of PENNVAX®-G DNA Prime Administered by Biojector® 2000 or CELLECTRA® Electroporation Device with Modified Vaccinia Ankara-CMDR Boost |
|
| Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand |
|
| Sensitivity of the Multispot HIV-1/HIV-2 rapid test using samples from human immunodeficiency virus type 1-positive individuals with various levels of exposure to highly active antiretroviral therapy. |
|
| Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection. |
|
| Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations |
|
| Sexually transmitted infections and sexual behaviour of deploying shipboard US military personnel: a cross-sectional analysis |
|
| Short communication: HIV type 1 genetic diversity among tea plantation workers in Kericho, Kenya |
|
| Short communication: Investigation of incident HIV infections among U.S. army soldiers deployed to Afghanistan and Iraq, 2001-2007. |
|
| Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. |
|
| Significant contribution of subtype G to HIV-1 genetic complexity in Nigeria identified by a newly developed subtyping assay specific for subtype G and CRF02_AG. |
|
| Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection |
|
| Standardization of a cytometric p24-capture bead-assay for the detection of main HIV-1 subtypes |
|
| Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee |
|
| Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. |
|
| Targeted deep sequencing of HIV-1 using the IonTorrentPGM platform |
|
| Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R- Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity |
|
| TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1 |
|
| The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope |
|
| Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques |
|
| Transcription regulation of human chemokine receptor CCR3: evidence for a rare TATA-less promoter structure conserved between drosophila and humans. |
|
| Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination. |
|
| Transfusion‐transmissible viral infections among US military recipients of whole blood and platelets during Operation Enduring Freedom and Operation Iraqi Freedom |
|
| Transfusion-transmitted human T-lymphotropic virus Type I infection in a United States military emergency whole blood transfusion recipient in Afghanistan, 2010. |
|
